Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
GLP-1s users significantly reduce consumption of less healthy foods
Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months
294 , R1807R1812 (2008)
Altered capacity for H2S production during the spontaneous differentiation of Caco-2 cells to colonocytes due to reciprocal regulation of CBS and SELENBP1
US$ 25.72
US$ 24.00
US$ 25.31
US$ 23.33
